menu
    • menu

    Company profile for Tallac Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tallac Therapeutics™ is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molec...
    Tallac Therapeutics™ is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tallac TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    866 Malcolm Road Suite 100, Burlingame, CA 94010
    Telephone
    Telephone
    (650) 866-1966
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tallactherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tallac-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tallac Therapeutics Presents TAC-001 Preclinical Data at AACR
    Tallac Therapeutics Presents TAC-001 Preclinical Data at AACR

    10 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240410584376/en

    BUSINESSWIRE
    10 Apr 2024
    Share Share
    Tallac Presents First Clinical Data for TAC-001 at SITC 2023
    Tallac Presents First Clinical Data for TAC-001 at SITC 2023

    03 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231103234375/en

    BUSINESSWIRE
    03 Nov 2023
    Share Share
    Tallac Therapeutics Announces Two Abstracts Accepted for Presentation
    Tallac Therapeutics Announces Two Abstracts Accepted for Presentation

    27 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230927484960/en

    BUSINESSWIRE
    27 Sep 2023
    Share Share
    Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
    Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

    19 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230119005166/en

    BUSINESSWIRE
    19 Jan 2023
    Share Share
    Tallac Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist
    Tallac Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist

    12 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221111005048/en

    BUSINESSWIRE
    12 Nov 2022
    Share Share
    Tallac Therapeutics Announces First Patient Dosed with TAC-001
    Tallac Therapeutics Announces First Patient Dosed with TAC-001

    28 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220728005280/en

    BUSINESSWIRE
    28 Jul 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search